First National Bank of Omaha Sells 33,110 Shares of Abbott Laboratories $ABT

Key Points

• First National Bank of Omaha reduced its Abbott Laboratories stake by 19.2%, selling 33,110 shares during the second quarter and retaining 139,704 shares valued at approximately $12.7 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Abbott exceeded quarterly expectations with $1.31 EPS and $12.59 billion in revenue, up 13% year over year, and issued 2026 EPS guidance of $5.45–$5.60. The company also maintains a quarterly dividend of $0.63, yielding about 2.2% annually.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and a $119.50 price target; recent product approvals for Libre Duo and Amulet 360 could support future growth, though the stock’s elevated valuation and recent underperformance remain risks.

First National Bank of Omaha cut its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 19.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 139,704 shares of the healthcare product maker's stock after selling 33,110 shares during the quarter. First National Bank of Omaha's holdings in Abbott Laboratories were worth $12,736,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC bought a new position in Abbott Laboratories during the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $112.63 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The business's 50 day moving average price is $102.61 and its two-hundred day moving average price is $100.22. The company has a market cap of $194.89 billion, a PE ratio of 36.45, a price-to-earnings-growth ratio of 2.16 and a beta of 0.59. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 earnings per share. The business's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories's payout ratio is presently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott's next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Analyst Ratings Changes

ABT has been the subject of a number of research analyst reports. Wolfe Research raised Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price for the company in a research note on Thursday, August 13th. Wells Fargo & Company lifted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a report on Friday, July 17th. JPMorgan Chase & Co. increased their target price on Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a research note on Friday, July 17th. The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a report on Wednesday, May 27th. Finally, Weiss Ratings raised shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source